Follow
VIVEK RUHELA
VIVEK RUHELA
Research Fellow, Mayo Clinic
Verified email at mayo.edu
Title
Cited by
Cited by
Year
RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome
G Kaur, V Ruhela, L Rani, A Gupta, K Sriram, A Gogia, A Sharma, ...
Blood cancer journal 10 (1), 6, 2020
232020
Characterizing the mutational landscape of MM and its precursor MGUS
A Farswan, A Gupta, L Jena, V Ruhela, G Kaur, R Gupta
American Journal of Cancer Research 12 (4), 1919, 2022
42022
BDL-SP: A Bio-inspired DL model for the identification of altered Signaling Pathways in Multiple Myeloma using WES data
V Ruhela, L Jena, G Kaur, R Gupta, A Gupta
American Journal of Cancer Research 13 (4), 1155, 2023
12023
miRPipe: A Unified Computational Framework for a Robust, Reliable, and Reproducible Identification of Novel miRNAs from the RNA Sequencing Data
V Ruhela, A Gupta, S Krishnamachari, G Ahuja, G Kaur, R Gupta
Frontiers in Bioinformatics, 71, 2022
1*2022
A Comprehensive Targeted Panel of 295 Genes: Unveiling Key Disease Initiating and Transformative Biomarkers in Multiple Myeloma
V Ruhela, R Oberoi, R Gupta, A Gupta
bioRxiv, 2023.10. 28.564536, 2023
2023
P-035: AI-based models for the identification of critical genetic biomarkers to distinguish MM from MGUS using the WES data
V Ruhela, A Farswan, A Gupta, K Sriram, G Kaur, R Gupta
Clinical Lymphoma Myeloma and Leukemia 21, S57, 2021
2021
Prognostic value of TMB and its association with overall survival in newly diagnosed multiple myeloma patients
RG Akanksha Farswan, Anubha Gupta, Vivek Ruhela, Lingaraja Jena, Gurvinder ...
CMMC Symposium, Sept 26-28, 2021, Cologne, Germany., 2021
2021
miRSim: Seed-based Synthetic Small Non-coding RNA Sequence Simulator
VR Ritu Gupta, Sriram Krishnamachari, Gaurav Ahuja, Anubha Gupta
Zenodo https://doi.org/10.5281/zenodo.6546356, 2021
2021
The system can't perform the operation now. Try again later.
Articles 1–8